Objective: Prepared tumor-targeting liposomes as delivery vectors for plasmid encoding short hairpin RNA interfering OC-2(psh OC-2).In vitro and in vivo antitumor experiments were conducted to investigate the effect of inhibiting OC-2 on the survival,migration and metastasis of breast cancer MCF-7 cells and its xenograft tumor model.Methods: The expression of OC-2 in clinical samples of breast cancer and its effect on overall survival were analyzed.Cationic liposomes with different formulation were prepared and their particle size distribution was further optimized,and then cRGD-modified cationic liposomes(cRGD-CL)with tumor targeting and high transfection efficiency were screened in 293 T and MCF-7 cells.The physiochemical properties of cRGD-CL were characterized,and its drug loading capacities including encapsulation efficiency,nucleic acid protection,in vitro toxicity,cellular uptake,the ability of lysosomal escape and transfection efficiency were also measured.Results: OC-2 was differentially expressed in clinical samples of breast cancer,and patients with high expression of OC-2 had shorter overall survival.The prepared cRGD-CL is nearly spherical with uniform particle size after extrusion and moderate positive charge,which has excellent drug loading performance,biological safety and tumor targeting.Silencing OC-2 promoted apoptosis of MCF-7 cells both in vitro and in vivo,and the capability of migration and metastasis reduced concurrently.Conclusion: The cationic liposome cRGD-CL prepared in this study has moderate positive charge,excellent drug loading performance,biological safety and tumor targeting,and the delivered OC-2 sh RNA can effectively inhibit the growth and migration of breast cancer MCF-7cells and xenograft tumor in vivo and in vitro. |